Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament

Medical Science Monitor

Volumn 14, Issue 8, 2008, Pages

  Halpern, John H ^a   Sherwood, Andrea R ^b   Passie, Torsten ^c   Blackwell, Kimberly C ^d   Ruttenber, A James ^e  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d ARIZONA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Assessment; Ayahuasca; Hallucinogens; Religious; Use Santo Daime

Indexed keywords

ALCOHOL;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; CEREMONY; CHILDHOOD; COMPARATIVE STUDY; CONDUCT DISORDER; DEMOGRAPHY; DRUG ABUSE; DRUG USE; FEMALE; HALLUCINATION; HEALTH; HISTORY; HUMAN; INTERVIEW; LIFESPAN; MALE; MEDICAL RESEARCH; MENTAL DISEASE; PHYSICAL EXAMINATION; PSYCHOLOGY; RELIGION; REMISSION; SAFETY; SCORING SYSTEM;

ADULT; AGED; BANISTERIOPSIS; DEMOGRAPHY; ETHNIC GROUPS; FEMALE; HALLUCINOGENS; HEALTH; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PERCEPTION; RELIGION; SAFETY; SUBSTANCE-RELATED DISORDERS;

EID: 50249189427     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. nd. Rochester (VT): Healing Arts Press, 2001
2. Callaway JC: Various alkaloid profiles in decoctions of Banisteriopsis caapi. J Psychoactive Drugs, 2005; 37: 151-55
3. Casale JF, Koles JE: Analysis of ayahuasca ('Santo Daime'). Microgram, 1995; 28: 296-99
4. Freedland CS, Mansbach RS: Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture, Drug Alcohol Depend, 1999; 54: 183-94
5. McKenna DJ, Towers GH, Abbott F: Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca. J Ethnopharmacol, 1984; 10: 195-223
6. Riba J, Rodriguez-Fornells A, Urbano G et al: Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacol (Berl), 2001; 154: 85-95
7. Office of Diversion Control, Drug Enforcement Administration, U.S. Department of Justice. http://www.deadiversion.usdoj.gov/drugs_concern/dmt/ dmt.htm. Accessed 12/30/2007
8. Office of Diversion Control, Drug Enforcement Administration, U.S. Department of Justice. http://www.deadiversion.usdoj.gov/drugs_concern/ cocaine/cocaine.htm. Accessed 12/30/2007
9. de Rios MD: Drug tourism in the Amazon. Anthropol Conscious, 1994; 5: 16-19
10. de Rios MD. Mea culpa: drug tourism and the anthropologist's responsibility. Anthropol News, 2006; 47: 20
11. Halpern JH, Pope HG Jr: Hallucinogens on the Internet: a vast new source of underground drug information. Am J Psychiatry, 2001; 158: 481-81.
12. Winkelman M: Drug tourism or spiritual healing? Ayahuasca seekers in Amazonia. J Psychoactive Drugs, 2005; 37: 209-18
13. Ruck CAP, Bigwood J, Staples R et al: Entheogens. J Psychedelic Drugs, 1979; 11: 145-46
14. nd ed. Campinas, Brazil: Mercado de Letras, 2004
15. Riba J, Valle M, Urbano G et al: Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metaboline excretion, and pharmacokinetics. J Pharmacol Exp Ther, 2003; 306: 73-83
16. Callaway JC, McKenna DJ, Grob CS et al: Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol, 1999: 65; 243-56
17. Shanon B: The antipodes of the mind: charting the phenomenology of the ayahuasca experience. Oxford: Oxford University Press, 2002
18. Grob CS, McKenna DJ, Callaway JC et al: Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis, 1996; 184: 86-94
19. Nichols DE: Hallucinogens, Pharmacol Therapeutics, 2004; 101: 131-81
20. Doering-Silveira E, Grob CS, de Rios MD et al: Ayahuasca in adolescence: a neuropsychological assessment. J Psychoactive Drugs, 2005; 37: 123-28
21. Doering-Silveira E, Lopez E, Grob CS et al: Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J Psychoactive Drugs, 2005; 37: 141-44
22. Groisman A, Sell AB: Healing power: neurophenomenology, culture, and therapy of Santo Daime. In: Winkelman M, Andritzky W (eds.): Yearbook of cross-cultural medicine and psychotherapy, vol 4. Berlin: VWM - Verlag für Wissenschaft und Bildung, 1996; 279-87
23. Santos RG, Landeira-Fernandez J, Strassman RJ et al: Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol, 2007; 112: 507-13
24. Yin M, Wade TD, Lawler-Heavner J, Ruttenber AJ: Computer-generated time lines for visualizing and editing epidemiological and biomedical data. Comput Methods Programs Biomed, 1998; 56: 23-29
25. First M, Spitzer R, Gibbon M, Williams J: Structured clinical interview for DSM-IV-TR Axis I disorders, research version, non-patient edition (SCID-I/NP) New York Biometrics Research, New York State Psychiatric Institute, 2001
26. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol, 1959; 32: 50-55
27. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry, 1960; 23: 56-61
28. Hamilton M: Development of arating scale; for primary depressive illness. Br J Soc Clin Psychol, 1967; 6: 278-96
29. Derogatis LR: SCL-90-R: administration, scoring and procedures manual. Minneapolis: National Computer Systems, Inc., 1994
30. Parrott AC, Kaye F: Uplifts, hassles and cognitive failures in cigarette smokers and non-smokers. Behav Pharmacol, 1999; 10: 639-46
31. Ward M, Wender P, Reimherr F: The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry, 1993; 150: 885-89
32. First M, Gibbon M, Spitzer R et al: Structured clinical interview for DSM-IV Axis II disorders (SCID-II). Washington DC: American Psychiatric Press, 1997
33. Parrott AC, Sisk E, Turner JJD: Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend, 2000; 60: 105-10
34. Miranda CT, Labigalini E, Tada C: Alternative religion and outcome of alcohol dependence in Brazil. Addiction, 1995; 90: 847
35. Barbosa PC, Giglio JS, Dalgalarrondo P: Altered states of consciousness and short-term psychological after-effects induced by the first time ritual use of ayahuasca in an urban context in Brazil. J Psychoactive Drugs, 2005; 37: 193-201
36. de Rios MD, Grob CS, Lopez E et al: Ayahuasca in adolescence: qualitative results. J Psychoactive Drugs, 2005; 37: 135-39
37. da Silveira DX, Grob CS, de Rios MD et al: Ayahuasca in addescence: a preliminary psychiatric assessment. J Psychoactive Drugs, 2005; 37: 129-33
38. Gable RS: Risk assessment of ritual use of oral Dimethyltryptamine (CMT) and Harmala alkaloids. Addiction, 2007; 102: 24-34
39. Halpern JH, Sherwood AR, Hudson JI et al: Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry, 2005; 58: 624-31